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Abstract 
It remains unclear whether biomarkers in the serum or cerebrospinal fluid (CSF) can be used 
for diagnosis or prognosis of spinal cord injuries (SCI). Therefore, a systematic review was 
undertaken to evaluate the prognostic or diagnostic value of serum and CSF biomarkers in 
assessing the severity of SCI and the outcome of patients. Two independent reviewers 
summarized the human studies retrieved from the electronic databases of Medline, Embase, 
Scopus and ISI Web of Science until April 2018. Seventeen studies were included (1065 
patients aged 16 to 94 years old). Although the findings of the included studies suggest that 
inflammatory and structural proteins may be useful in assessing the severity of SCI and 
prediction of neurological outcome, the level of evidence is generally low. Given limitations 
to the available evidence, further investigation in this field is required using large prospective 
datasets with rigorous analysis of sensitivity, specificity and prediction. 
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1.1 Introduction 
Spinal cord injury (SCI) is one of the most serious injuries that can severely affect a person’s 
function. The incidence of SCI has been reported at 10.5 cases per 100,000 people (1). 
Epidemiological studies conducted in the last decade have clearly shown that SCI mostly 
affects younger adults (average age of 34.0 to 39.8 years old) (1, 2). No effective treatment 
has been introduced that can significantly improve sensory and motor function in SCI 
patients (3); however, considerable improvements have been made in secondary care of these 
patients that have led to a decrease in their mortality rates (4). 
 
After primary stabilization of patients in the first few days after a SCI, the patients and their 
families want to know whether they can return to their normal independent lives or not (5). 
Therefore, a correct assessment of the severity of the SCI is of utmost importance for 
predicting the functional outcome of the patients. Currently, SCIs are classified according to 
the American Spinal Injury Association (ASIA) Impairment Scale (AIS), which is a revised 
version of Frankel criteria (6). Although the AIS criteria is the most commonly used tool for 
classification SCIs, it has some limitations (7) that have led researchers to search for other 
auxiliary tools for accurate assessment of the patients’ status such as magnetic resonance 
imaging (MRI) (8-10), electrophysiological evaluations and biomarker measurement in the 
serum and cerebrospinal fluid (CSF) (11-15). Biomarkers are excreted into serum and CSF 
during various stages of an SCI (16, 17) and they include inflammatory factors and structural 
proteins such as S100 calcium-binding protein β (S100-β), Tau protein and neuron specific 
enolase (NSE) (18-21). Current evidence raises the question of whether these biomarkers 
could be used as a tool for an accurate classification of SCI or not, for which no concrete 
answer has been established. Hence, the present systematic review has aimed to gather the 
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findings of all the studies that have assessed the predictive or diagnostic value of serum or 
CSF biomarkers in detecting the severity of SCI and the outcome of affected patients, in 
search of a consensus regarding this question.  
 
1.2 Methods 
1.2.1 Study design 
The present study was designed to investigate the diagnostic value of serum and CSF 
biomarkers through a systematic review. The study was carried out according to the guideline 
for the systematic reviews and meta-analyses in observational studies (MOOSE) guideline 
(22).  
 
1.2.2 Search strategy 
A search was performed in the electronic databases and the bibliographies of relevant articles. 
Search in grey literature was also carried out as another source of possible related studies. 
The systematic search of electronic databases was conducted with the guidance of a librarian 
and under supervision of an experienced researcher in the field of SCI. Keywords for the 
search were selected according to the Mesh database and Emtree, after consultation with a 
neurosurgeon and review of the titles and abstracts of relevant articles. Then, the search 
strategy was defined for each database, according its specific guides. Further details on the 
search and data summarization methods can be found in the previous meta-analyses of the 
authors (23, 24). The electronic databases of Medline, Embase, Web of Science and Scopus 
were searched until April 2018. The search strategy for the Medline database is presented in 
Table 1 as a template.  
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1.2.3 Selection criteria 
The human studies investigating the diagnostic value of serum and CSF biomarkers and their 
predictive value for the patients’ outcomes were included in the present study. Lack of a 
control group or a group without any changes in neurological status in follow up, inclusion of 
chronic or non-traumatic injuries and not describing the protocol used for measurement of the 
biomarker were considered as the exclusion criteria.  
 
1.2.4 Data collection 
Two independent reviewers performed screening, summarization and the quality control of 
the included articles. Any disagreement was resolved through discussion with a third person. 
Articles were summarized based on a checklist designed according to the PRISMA statement 
guidelines (25). Extracted information included data related to the methods of the study, 
characteristics of the case and control groups (age, gender and SCI mechanism), number of 
included cases, outcome and possible biases. Diagnostic value of the biomarker in detection 
of SCI and its prognostic value for neurological improvement were the outcomes evaluated in 
the study. The plot digitizer software (version 2.0; available in: 
http://plotdigitizer.sourceforge.net) was used to extract the information from the articles that 
presented their results as charts. 
 
1.2.5 Quality control of the studies 
Quality assessment of the articles was performed per QUADAS-2 guidelines (26). Inter-rater 
reliability was evaluated to determine the agreement between the two reviewers. 
Disagreements were resolved through discussion with a third researcher.  
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1.3 Results 
1.3.1 Characteristics of the articles 
The systematic search yielded 1072 non-repetitive articles. The primary screening downsized 
this number to 56 potentially relevant studies, and eventually after review of these articles’ 
full texts, 16 studies were included (7, 20, 27-40) (Figure 1). These papers included data from 
1031 subjects (age range of 16 to 94 years). Seven studies were cohort (7, 20, 34-36, 38, 40), 
seven were case-control (27, 28, 31-33, 37, 39) and two were cross-sectional (29, 30). The 
severity of injury ranged from A to D, according to the AIS. The duration between injury and 
biomarker measurement varied from zero to 90 days.  
 
Evaluated biomarkers were categorized into three groups of inflammatory factors, structural 
proteins and others (nitric oxide, stem cell growth factor beta and hepatocyte growth factor). 
Inflammatory factors included interleukins (ILs), chemokines and other cytokines. Structural 
proteins included Tau protein, S100-β protein, glial fibrillary acidic protein (GFAP), matrix 
metalloproteinases (MMPs), neurofilaments, high mobility group box 1 protein (HMGB1) 
and NSE. Tables 2 and 3 present a summary of the included articles.  
 
Of these 16 studies, 10 had evaluated the diagnostic value of the aforementioned biomarkers 
for SCI (20, 27, 28, 31, 33-35, 37, 39, 40) and seven focused on their prognostic value (7, 29, 
30, 32, 36, 38, 39) for neurological improvement/remission. 
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1.3.2 Quality control of the studies 
Quality assessment of the articles showed that patient selection of 62.5% and 18.8% of 
eligible studies have high and unclear risk of bias, respectively. Moreover, risk of bias for 
index test was unclear in 68.8% of the studies. Only 6.2% of the articles had unclear risk of 
bias for reference standard, while 31.2% and 6.2% of flow and timing of included studies had 
proposed high and unclear risk of bias, respectively. The applicability of patient selection was 
also at high risk in 12.5% of the studies (Table 4 and Figure 2). 
 
1.3.2.1 Diagnostic value of serum and CSF biomarkers for SCI 
Ten studies had evaluated the diagnostic value of serum and CSF biomarkers for SCI (20, 27, 
28, 31, 33-35, 37, 39, 40). These biomarkers included various cytokines (ILs, chemokines 
and other cytokines) and structural proteins (MMPs, GFAP, S100-B, NSE, neurofilaments, 
Tau protein, and HMGB1) (Table 2).  
 
a) Serum level of biomarkers in diagnosis of SCI 
- Diagnostic value of ILs for SCI 
The included studies investigated the value of IL-1, IL-5, IL-6, IL-9, IL-10, IL-17, IL-16 and 
IL-18 in diagnosis of SCI. The findings of this section are indicative of a significant change 
in the serum concentration of these ILs after SCI. For instance, Zaaqoq et al. reported 
significant decreases in the serum level of IL-1β on days 1, 4, 7, 9, 13 and 14 after SCI, while 
no considerable difference is appreciated between the case and control groups on other days. 
A similar pattern was reported for IL-5, with its levels significantly lower in the case group 
on the first four days after SCI, and on days 7, 9 and 14 (40).  
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Bank et al. also showed that the serum level of IL-6 is significantly higher in patients with 
SCI, on the first 3 days, days 4 to 7 and day 14 after the injury (28). On the contrary, Zaaqoq 
et al. reported no considerable changes in IL-6 levels in the first 14 days after the injury. 
These two studies showed a significant increase in levels of IL-9, IL-10, IL-16 and IL-18 in 
the first days following SCI along with a significant decrease in levels of IL-13 and IL-17, 
compared to the control group (28, 40). 
 
Overall, these findings are shown a significant change in the levels of ILs after SCIs, which 
renders them suitable candidates for diagnosis of these injuries (Table 5). 
 
- Diagnostic value of chemokines for SCIs    
Chemokines are other factors that show increased concentrations after SCI. Included articles 
had assessed the value of chemokine (C-X-C motif) ligand (CXCL)-1, CXCL-2, CXCL-12, 
chemokine (C-C motif) ligand (CCL)-4, monocyte chemotactic protein (MCP)-l and 
inducible protein-10 (IP-10) in diagnosis of SCIs. 
 
According to Bank et al. study the circulating level of CXCL-1 is significantly higher in SCI 
patients compared to healthy controls during the first week after the injury, and on days 11 to 
14 (28). In another study, Hassanshahi et al. reports this level to be only significantly 
increased on day 7 after the SCI. CXCL-9 is another biomarker with increased concentrations 
in patients with SCI on day 7 after their injury. The levels of CXCL-10 and CXCL-12 also 
rise in the first week after injury and could stay at a high level until day 28 (31). 
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The results of the studies that had evaluated the serum levels of CCL-4 were contradictory, 
with Bank et al. reporting a significant increase in its level after SCIs, while Zaaqoq et al. 
found a significant drop in SCI patients (28, 40) (Table 5). 
 
- Diagnostic value of other cytokines for SCI  
SCI affects the serum levels of migration inhibitory factor (MIF) and interferon gamma. 
Zaaqoq et al. reported a significant drop in serum levels of interferon gamma immediately 
after SCI and during the first week after it, compared to healthy controls (40). In the second 
week, the differences between the two groups are not significant and the concentrations 
return to normal levels. Bank et al. found a significant rise in MIF levels of patients with SCI; 
however, this increase is only observed on day 7 after the injury, and it returns to normal 
afterwards (28). 
 
- Diagnostic value of structural proteins for SCI 
As a result of injury in central nervous system, structural proteins are released into the serum. 
Increased levels of these biomarkers could be valuable for detection of SCI. In 2017, 
Moghaddam et al. reported a significant rise in MMP-8 serum levels in the first 48 hours after 
SCI, while no significant changes in concentrations of MMP-9 and MMP-2 were observed 
(35). GFAP is another structural protein that was investigated by Ahadi et al., who found a 
prominent increase in its levels within the first 48 hours, followed by a quick return to base 
levels after 72 hours. These researchers report a similar trend for the heavy subunit of 
neurofilaments, with its concentrations increasing within the first 48 hours after an injury and 
a return to that of the healthy group after 72 hours (27). Serum levels of neurofilament light 
chain after complete and incomplete SCIs were also reported by Kuhle et al. to be 
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significantly higher in the case group compared to the control group in the first week after the 
injury (34).  
 
Two studies assessed the value of NSE for diagnosis of SCI. In the first one conducted by 
Wolf et al. in 2014, no considerable difference was observed in the level of this biomarker 
between the two groups of case and control within the first 24 hours after the injury (20). On 
the other hand, in 2015, Ahadi et al. reported a significant increase in NSE’s serum levels in 
the first 48 hours after SCI, which tends to return to normal levels by the third day (27). Wolf 
et al. also assessed the changes in S-100β levels and found no considerable changes after SCI 
(20). In addition, serum concentration of HMGB1 showed a statistically significant raise in 
SCI patients (37) (Table 5). 
 
b) CSF level of biomarkers in diagnosis of SCI 
Two studies assessed the diagnostic value of CSF level of heavy subunit of neurofilaments 
(39) and nitric oxide (33) in detection of SCI. Ungureanu et al. confirmed a substantial 
increase in CSF levels of heavy subunit of neurofilaments during the first three days between 
SCI patients and the control group (39). However, Hoska et al depicted nitric oxide levels did 
not differ significantly between SCI patients and uninjured controls (30).  
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1.3.2.2 Prognostic value of serum and CSF biomarkers for neurological 
improvements/remission 
The prognostic value of serum and CSF biomarkers for neurological improvements/remission 
had been evaluated in 7 studies (7, 29, 30, 32, 36, 38, 39). The biomarkers in this section 
were categorized into two groups of cytokines and structural proteins (Table 6).  
 
a) Serum level of biomarkers in prognosis of SCI 
- Prognostic value of IL1-β 
Only one study evaluated the prognostic value of serum level of IL-1β in SCI (29). In this 
regard, Biglari et al. found IL-1 to have no prognostic value for neurological improvement 
after an SCI (Table 6).  
 
- Prognostic value of chemokines 
The studies included in this section had assessed the prognostic value of CCl-2, CCl-3, CCL-
4, and CXCL-5 for neurological status of the patients. Heller et al. also found the levels CCL-
2 and CCL-4 to be significantly lower in the first and 9 hours after admission, in patients who 
went through neurological improvements, while no considerable changes were reported for 
the levels of and CCL-3 and CXCL-5 (32). 
 
The serum levels of tumour necrosis factor – α (TNF- α) were also reported by Biglari et al. 
to be significantly lower at hour 9 after the SCI, in patients who had neurological 
improvements compared to other SCI subjects (12-week follow up) (29). These researchers 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
observed no significant differences in TNF- α levels between the two groups at other time 
points (Table 6). 
 
- Prognostic value of other cytokines 
Growth factors such as insulin-like growth factor 1 (IGF-1) and tumour growth factor β1 
(TGF- β1) were two of the most commonly assessed chemokines in regards to prognosis of 
SCI. Febert et al. showed that TGF- β1 is not a suitable prognostic factor for SCI patients 
(30). However, they found a considerable rise in levels of serum cluster of differentiation 95 
ligand (sCD95L) on day 7 after an injury in patients who had neurological improvement. This 
change was transient and the concentration of this chemokine lowered back to that of the 
subjects with no neurological improvements. As for the IGF-1, in another study conducted by 
Moghaddam et al., this chemokine was reported to rise in the subacute and chronic phases 
(days 7, 14, and 56 post-SCI) in the patients with neurological improvement (36). 
 
- Prognostic value of structural proteins 
Moghaddam et al. have suggested that serum levels of MMP-8 in the first 24 hours after 
injury could be good prognostic marker for perdition of neurological outcome of the patients. 
The serum concentration of this biomarker was found to be significantly lower in patients 
with neurological remission compared to other patients, but no considerable changes were 
appreciated in the levels of MMP-2 and MMP-2 (35). 
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Kuhle et al. refers to neurofilament light chain as a prognostic marker for neurological 
improvement in SCI patients. Their results show a significant increase in the serum levels of 
this biomarker in the first 24 hours, which stays at a high level until one week after the injury. 
The concentration was found to be much higher among patients with poor outcomes (34) 
(Table 6).  
 
b) CSF level of biomarkers in prognosis of SCI 
- Prognostic value of ILs 
Kwon et al. reported the mean concentrations of IL-6 and IL-8 in the CSF to be significantly 
lower in the first 24 hours after injury, among patients with neurological improvements 
compared with subjects with no changes in neurological status (7) (Table 6).  
 
- Prognostic value of chemokines 
One study included in this section had assessed the prognostic value of MCP-1 for 
neurological status of the patients. Kwon et al.  reported the CSF level of MCP-1 to be 
significantly lower in patients who showed neurological improvements, compared to the rest 
of the patients (7) (Table 6). 
 
- Prognostic value of structural proteins 
The prognostic value of CSF level of neurofilaments had been investigated in two of the 
articles. Pouw et al. argued that the CSF levels of neurofilament heavy chain in the first 24 
hours after SCI cannot be a useful prognostic factor for neurological outcome of these 
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patients (38). In another study with a 12 to 18-months follow up of patients, Ungureanu et al. 
showed that this biomarker is able to predict the outcome of patients when measured in the 
first 6 hours, but its levels do not show a significant difference when measured after 24 hours 
(39). 
 
Two of the studies included in our review measured the CSF levels of GFAP in the first 24 
hours after SCI. Kwon et al. reported higher levels of GFAP in patients with no neurological 
improvements within 6 months of the injury (7). In addition, Pouw et al. found a significant 
correlation between the CSF levels of GFAP with neurological remission in SCI patients 
(38). 
 
S100-β, Tau protein and NSE also increase in SCI patients and this rise could be correlated 
with the severity of injury (7, 38). Kwon et al. confirmed that CSF levels of S100-β and Tau 
protein is significantly higher in the first 24 hours after SCI in patients with no neurological 
improvement compared to other cases. However, Pouw et al. reported no significant 
difference in the concentration of NSE between the two-mentioned group of patients (38) 
(Table 6). 
 
1.4 Discussion 
The present systematic review collected available evidence on the value of serum and CSF 
biomarkers in diagnosis of SCI and prognosis of neurological improvement in affected 
patients. This study showed that overall, the concentration of inflammatory factors and 
structural protein changes in the serum and CSF in response to an SCI. After the injury, the 
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serum and CSF levels of IL-1β, IL-5, and IL-17 drop while the concentration of IL-6, Il-10, 
IL-16, IL-18, CXCL-1, CXCL-9, CXCL-10, CXCL-12, and MIF increases. There is 
disagreements between the studies regarding the changes in the levels of CCL-4. A 
significant rise also occurs in the levels of the structural proteins MMP-8, GFAP, 
neurofilaments, NSE, S100-β and HMGB1.  
 
Changes in the levels of inflammatory factors after an SCI is an expected observation, since 
after any type of injury the inflammatory cascade is activated which leads to increase 
concentrations of anti-inflammatory (IL-10, IL-6 and IL-9) and decrease inflammatory (IL-
1β, IL-5 and IL-17) cytokines involved in the process. Previous studies have shown that there 
is a substantial immunosuppression after SCI (29, 41). Part of this inhibitory function seems 
to be related to the level of IL-10 (40). The increased level of IL-10 may reduce neuronal 
apoptosis and decrease caspase activity. These anti-inflammatory effects of IL-10 partially 
inhibit the secondary damage following SCI (42). This is an endogenous protective 
mechanism.  
 
Knowledge about the prognosis of SCI patients is one of the most challenging topics in the 
management of these patients, since clinical examinations performed in the first few days 
after an insult cannot correctly determine the severity of the injury. Serum biomarkers could 
potentially provide a better perception of the injury’s severity for the medical team. The 
findings of this systematic review indicated that the levels of inflammatory proteins such as 
IL-6, IL-8, CCL-2, CCL-4, MCP-1, TNF-α, MMP-8 and structural proteins including GFAP, 
S100-β and Tau are significantly lower in patients with neurological improvements during the 
treatment period, compared to subjects with no changes in neurological functions. This 
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observation also seems logical, since lower levels of these biomarkers represent a milder 
injury to the spinal cord, and such cases are expected to show better neurological 
improvements.  
 
One of the limitations of the present review can be attributed to the fact that few of the 
included studies used rigorous statistical methods to assess the data. For example, only 5 of 
the studies reported diagnostic/prognostic accuracy of the serum and CSF biomarkers for the 
assessment of the severity of SCI at baseline and prognosis of neurological outcome (7, 32, 
35, 36, 43). The rest of the studies only compared the mean concentration of the biomarkers 
between the two groups, a method that is associated with certain limitations in evaluating 
diagnostic value. For example, Heller et al. state that among their evaluated biomarkers only 
CCL-2 is able to predict AIS conversion, while the mean levels of the other serum and CSF 
factors they assessed also showed significant differences between the two groups of cases 
with and without AIS conversion (32). Therefore, a significant difference in the mean 
concentration of a biomarker between the two groups might not directly translate to that 
biomarker being an appropriate prognostic factor. The quality assessment of the included 
studies showed that most of them had a high risk of bias in their sample selection. The quality 
status for index text was also not determined in 64.7% of the studies. Moreover, the majority 
of the included studies were case-control and cohort studies or had performed their 
recruitment through a convenience sampling method. Accordingly, the findings reported by 
these articles have a low level of evidence. 
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The main problem with biomarkers is that their circulating/CSF concentration have an 
association with the amount of parenchyma that is affected following injury. Thus, it was 
better to evaluate the biomarkers association to injury severity.  At the first, the authors 
decided to report the findings based on the severity of the injury. However, with a closer look 
to the included studies, it was found that only six studies (two studies in diagnostic and two in 
predictive values and two in both) reported the findings according to severity of SCI (27, 34, 
36-39). In addition, the categorizing of the patients based on the severity of injury had 
considerable diversity among the studies. Therefore, it is not possible to report the results 
based of severity of injury. Finally, concomitant traumatic brain injury (TBI) and SCI could 
be falsely alter serum/CSF levels of biomarkers. Eligibility of concomitant TBI in four 
studies was unclear (28, 31, 34, 37) while other 12 studies excluded the TBI patients. 
Therefore, it seems that the prevalence of concomitant of brain injury in included subjects 
were low.  
 
1.5 Conclusion 
The findings of this review indicate that changes in the serum and CSF levels of 
inflammatory factors and structural proteins occur in response to SCI. Therefore, 
inflammatory factors and structural proteins can be potentially used as biomarkers for 
detection of SCI and can predict the subsequent neurological improvement. Although the 
findings of the included studies suggest that inflammatory and structural proteins may be 
useful in assessing the severity of SCI and prediction of neurological outcome, the level of 
evidence is generally low. Given limitations to the available evidence, further investigation in 
this field is required using large prospective datasets with rigorous analysis of sensitivity, 
specificity and prediction. 
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Figure Captions 
Figure 1: PRISMA flow diagram of present systematic review. The systematic search yielded 
1072 non-repetitive articles. Finally, 16 studies were included. 
Figure 2: Quality assessment of included studies based on Quality Assessment of Diagnostic 
Accuracy Studies version 2.0 (QUADAS-2) guideline. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1: Search query for Medline (via Ovid)  
Search terms 
1. Spinal Cord Injuries/ OR Quadriplegia/ OR Paraplegia/ OR (Spinal Cord/ AND "Wounds and 
Injuries"/) OR (("Spinal Cord" adj (Injur* OR Contus* OR Trauma* OR Posttrauma* OR 
Transect* OR Lacerat* OR Compromi* OR Lesion* OR Rupture*)) OR Quadriplegi* OR 
Paraplegi* OR Tetraplegi* OR Quadripares?s OR ((Trauma* OR Posttrauma*) adj 
Myelopath*)).ti,ab. 
2. Biomarkers/ OR Glial Fibrillary Acidic Protein/ OR S100 Calcium-Binding Protein A4/ OR 
S100 Proteins/ OR Intermediate Filaments/ OR Phosphopyruvate Hydratase/ OR 
Neurofilament Proteins/ OR S100 Calcium Binding Protein beta Subunit/ OR (Biomarker* 
OR Bioindicator* OR (Biologic* adj Indicator*) OR ((Biochemical OR Biologic* OR 
Clinical OR Immun* OR Laboratory OR Serum OR Surrogate Viral) adj Marker*) OR 
"Surrogate Endpoint*" OR "Surrogate End Point*" OR Astroprotein OR "Glial Fibrillary 
Acidic Protein" OR "Glial Intermediate Filament Protein" OR "Glial Fibrillary Acid Protein" 
OR "GFA Protein" OR "G F Protein" OR "GF Protein" OR "Glia Fibril Acidic Protein" OR 
"Glia Fibrillary Acid Protein" OR "Glia Fibrillary Acidic Protein" OR "Glia Filament 
Protein" OR "Glial Acidic Fibrillary Protein" OR "Glial Filament Protein" OR "Protein GF" 
OR "Protein GFA" OR "Metastasin" OR "Placental Calcium Binding Protein" OR 
"Calvasculin Protein" OR "Fibroblast Specific Protein 1" OR "S100A4" OR "FSP 1" OR 
FSP1 OR MTS1 OR "S 100A4" OR "Phosphopyruvate Hydratase" OR "2 Phospho D 
Glycerate Hydrolase" OR "2 Phospho D Glycerate Hydro Lyase" OR "2 Phosphoglycerate 
Dehydratase" OR "Phosphopyruvic Hydratase"OR "Phospho D Glycerate Hydrolyase" OR 
"E.C. 4.2.1.11" OR "EC 4.2.1.11" OR Enolase OR "Intermediate Filament*" OR 
"Intermediate Size Filament*" OR Neurofilament* OR Tonofilament* OR Calvasculin OR "S 
100" OR "S100" OR "S 100beta" OR "S 100b" OR "S100beta" OR "S100B").ti,ab. 
3. 1 AND 2 
4. Exp Animals/ NOT Humans.sh. 
5. 3 NOT 4 
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Table 2: Summary of included studies that assessed the diagnostic value of various biomarkers in detection of spinal cord injury 
 
Author; Year; 
Country 
 Design 
Non-
SCI ; 
SCI 
Control 
definition 
Age Male 
Severity 
(AIS) 
Injury 
level 
Follow up 
duration 
(day) 
Sample 
location 
Time to 
sample (day) 
Storage 
Time 
storage 
Biomarkers 
A) Inflammatory biomarkers 
1- Interleukins 
 
Bank, 2015;  
USA 
CCS 18 ; 14 Healthy 19 to 91 32 A to D 
All 
level 
15 Serum 0 to 15 NR NR 
IL-6; IL-9; IL-16; 
IL-18 
 
Zaaqoq,  2014; 
USA 
RCS 21 ; 21 
Non-SCI 
patients 
37+3 32 A to D 
All 
level 
14 Serum 1 to 14 NR NR 
IL-1; IL-5; IL-6; IL-
10; IL-17 
2- Chemokines 
 
Bank, 2015;  
USA 
CCS 18 ; 14 Healthy 19 to 91 32 A to D 
All 
level 
15 Serum 0 to 15 NR NR CXCL-1; CCL-4 
 
Hassanshahi, 
2013; Iran 
CCS 100 ; 78 
Healthy 
and non-
SCI 
patients 
33.3 ± 
1.6 
NR A to D 
All 
level 
90 Serum 0 to 90 NR NR 
CXCL-1; CXCL-9; 
CXCL-10; CXCL-
12 
 
Zaaqoq, 2014; 
USA 
RCS 21 ; 21 
Non-SCI 
patients 
37+3 32 A to D 
All 
level 
14 Serum 1 to 14 NR NR 
MCP-1; IP-10; 
CCL-4 
3- Interferons 
 
Zaaqoq, 2014; 
USA 
RCS 21 ; 21 
Non-SCI 
patients 
37+3 32 A to D 
All 
level 
14 Serum 1 to 14 NR NR INF-γ 
4- Other Cytokines 
 
Bank, 2015;  
USA 
CCS 18 ; 14 Healthy 19 to 91 32 A to D 
All 
level 
15 Serum 0 to 15 NR NR MIF 
B) Structural  biomarkers 
1- MMPs 
 
Moghaddam, 
2017; Germany 
RCS 10 ; 20 NA 43 to 88 21 A to C 
All 
level 
90 Serum 0 to 90 -80 NA 
MMP-2; MMP-8; 
MMP-9 
2- Neurofilaments 
 
Ahadi; 2015,  
Iran 
CCS 9 ; 26 Healthy 16 to 64 30 A to D 
All 
level 
3 Serum 1 to 3 -80 NR NF-H 
 
Kuhle, 2014;  
UK 
CS 67 ; 10 Healthy 22-62 49 C to D 
All 
level 
7 Serum 0 NA NA NF-L 
 
Ungureanu, 
2014; Romania 
CCS 6 ; 15 Healthy 21-59 NR A to D 
Thoraci
c-
24 CSF 0 to 1 NR NR NF-H 
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cervical 
3- GFAP 
 Ahadi; 2015; Iran CCS 9 ; 26 Healthy 16 to 64 30 A to D 
All 
level 
3 Serum 1 to 3 -80 NR GFAP 
4- NSE 
 Ahadi; 2015; Iran CCS 9 ; 26 Healthy 16 to 64 30 A to D 
All 
level 
3 Serum 1 to 3 -80 NR NSE 
 
Wolf; 2014; 
Austria 
CS 22 ; 12 NA 16-94 20 A to D 
All 
level 
18 Serum 1 NR NR NSE 
5- S100-β 
 
Wolf; 2014; 
Austria 
PCS 22 ; 12 NA 16-94 20 A to D 
All 
level 
18 Serum 1 NR NR S100-B 
6- HMGB1 
 
Papatheodorou; 
2017; USA 
CCS 51 ; 11 Healthy 19-89 63 A to D 
Thoraci
c-
cervical 
7 Serum 0 to 7 NR NR HMGB1 
C) Other biomarkers 
 
Hosaka; 2008; 
Japan 
CCS 36 ; 25 Healty 30-85 NR C to D 
Cervica
l 
510 CSF 0 to 30 NR NR NOx 
 
Bank, 2015;  
USA 
CCS 18 ; 14 Healthy 19 to 91 32 A to D 
All 
level 
15 Serum 0 to 15 NR NR HGF; SCGF-β 
AIS: American Spinal Injury Association Impairment Scale; CCL: chemokine (C-C motif) ligand; CCS: Case-control study; Cross: Cross sectional; CS: 
Cohort study; CSF: Cerebrospinal fluid; CXCL: Chemokine (C-X-C motif) ligand; GFAP: Glial fibrillary acidic protein; HGF: Hepatocyte growth factor; 
HMGB1: High mobility group box 1 protein; IL: Interleukin; INF-γ: Interferons-γ; IP-10: Inducible protein-10; MCP: Monocyte chemotactic protein; MIF: 
migration inhibitory factor; MMP: Matrix metalloproteinase; NA: Not applicable; NFH: Neurofilament heavy chain; NF-L: Neurofilament light chain; NOx: 
Nitric oxide; NR: Not reported; NSE: Neuron specific enolase; RCS: Retrospective cohort study; SCGF-β: Stem cell growth factor beta; SCI: Spinal cord 
injury 
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Table 3: Summary of included studies that assessed the prognostic value of various biomarkers in prediction of neurological improvement 
 Author; 
Year; 
Country 
Design 
Non-
SCI ; 
SCI 
Control 
definition 
Age Male 
Severit
y (AIS) 
Injury 
level 
Follow up 
duration 
(day) 
Sample 
location 
Time to 
sample 
Storage 
Time 
storage 
Biomarker 
A) Inflammatory biomarkers 
1- Interleukins 
 Biglari; 2015; 
Germany 
Cross 7; 16 NA 18 to 86 16 A to D All level 84 Serum 0 to 90 -80 NR IL-1β 
 Kwon; 2017; 
Canada 
CS 22; 26 NA 
41.9 – 
14.9 
39 A-C All level 180 CSF 1 NA NA IL-6; IL-8 
2- Chemokines 
 Heller; 2017; 
Germany 
CCS 30 Healthy 10; 10 21 A to E All level 84 Serum 0 to 90 -80 NR 
CCL-2; CCL-3; 
CCL-4; CXCL-5 
 Kwon; 2017; 
Canada 
CS 22; 26 NA 
41.9 – 
14.9 
39 A to C All level 180 CSF 1 NA NA MCP-1 
3- Other cytokines 
 Biglari; 2015; 
Germany 
Cross 7; 16 NA 18 to 86 16 A to D All level 84 Serum 0 to 90 -80 NR TNF-α 
 Moghaddam; 
2016; 
Germany 
CS 26; 19 NA 
42.36 ± 
19.07 
35 A to C All level 90 Serum 1 -80 NA IGF-1 
 Ferbert; 2017; 
Germany 
Cross 9; 14 NA 18 to 86 16 A to D All level 84 Serum 0 to 90 -80 NR 
sCD95L; IGF-1; 
TGF-β1 
B) Structural  biomarkers 
1- MMPs 
 Moghaddam; 
2017; 
Germany 
RCS 10; 10 Na 43 to 88 21 A to C All level 90 Serum 0 to 90 -80 NA 
MMP-2; MMP-8; 
MMP-9 
2- Neurofilaments 
 Pouw; 2014; 
Canada 
CS 8; 8 NA 18-84 10 A to D 
Thoracic-
cervical 
12 CSF 1 -80 NR NFH 
 Kuhle, 2014;  
UK 
CS 67 ; 10 Healthy 22-62 49 C to D All level 7 Serum 0 NA NA NF-L 
 Ungureanu; 
2014; 
CCS 11; 4 Healthy 21-59 NR A to D 
Thoracic-
cervical 
24 CSF 0 to 1 NR NR NFH 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Romania 
3- GFAP 
 Kwon; 2017; 
Canada 
CS 22; 26 NA 
41.9 – 
14.9 
39 A to C All level 180 CSF 1 NA NA GFAP 
 Pouw; 2014; 
Canada 
CS 8; 8 NA 18-84 10 A to D 
Thoracic-
cervical 
12 CSF 1 -80 NR GFAP 
4- NSE 
 Pouw; 2014; 
Canada 
CS 8; 8 NA 18-84 10 A to D 
Thoracic-
cervical 
12 CSF 1 -80 NR NSE 
5- S100-β 
 Kwon; 2017; 
Canada 
CS 22; 26 NA 
41.9 – 
14.9 
39 A to C All level 180 CSF 1 NA NA S100-B 
 Pouw; 2014; 
Canada 
CS 8; 8 NA 18-84 10 A to D 
Thoracic-
cervical 
12 CSF 1 -80 NR S100-B 
6- Tau 
 Kwon; 2017; 
Canada 
CS 22; 26 NA 
41.9 – 
14.9 
39 A to C All level 180 CSF 1 NA NA Tau 
 Pouw; 2014; 
Canada 
CS 8; 8 NA 18-84 10 A to D 
Thoracic-
cervical 
12 CSF 1 -80 NR Tau 
AIS: American Spinal Injury Association Impairment Scale; CCL: chemokine (C-C motif) ligand; CCS: Case-control study; Cross: Cross sectional; CS: 
Cohort study; CSF: Cerebrospinal fluid; CXCL: Chemokine (C-X-C motif) ligand; GFAP: Glial fibrillary acidic protein; IGF-1: Insulin-like growth factor 1; 
IL: Interleukin; MCP: Monocyte chemotactic protein; MMP: Matrix metalloproteinase; NA: Not applicable; NFH: Neurofilament heavy chain; NF-L: 
Neurofilament light chain; NR: Not reported; NSE: Neuron specific enolase; RCS: Retrospective cohort study; sCD95L: Serum cluster of differentiation 95 
ligand; SCI: Spinal cord injury; TGF- β1: Tumour growth factor β1; TNF-α: Tumour necrosis factor-α 
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Table 4: Risk of bias and applicability of included studies based on QUADAS-2 guideline.  
Author, year 
Risk of bias  Applicability 
Patient 
selection 
Inde
x 
test 
Reference 
standard 
Flow 
and 
Timing 
 
Patient 
selection 
Index 
test 
Reference 
standard 
Ahadi, 2015  ?       
Bank, 2015  ?       
Biglari, 2015 ? ?       
Ferbert, 2016 ?        
Hassanshahi, 2013  ? ?      
Heller, 2017  ?       
Hosaka, 2008  ?       
Kuhle, 2014         
Kwon, 2017         
Moghaddam, 2016         
Moghaddam, 2017         
Papatheodorou, 
2017 
 ?       
Pouw, 2014  ?       
Ungureanu, 2014  ?       
Wolf, 2014 ? ?  ?     
Zaaqoq, 2014  ?  ?     
: Low risk; : High risk; ?: Unclear 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 5: Serum and CSF level of various biomarker in spinal cord injured patients compered to non-
SCI subjects (diagnostic value)  
Biomarkers 
Time after SCI (day) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 28 90 
Serum level                 
IL-1β                 
Zaaqoq; 2014  no no  no no  no  no no no   --- --- 
IL-5                 
Zaaqoq; 2014     no no  no no no no no no  --- --- 
IL-6                 
Bank; 2015 --- ---  --- --- ---  --- --- --- no --- ---  --- --- 
Zaaqoq; 2014 no no no no no no no no no no no no no no --- --- 
IL-9                 
Bank; 2015 --- ---  --- --- --- no --- --- --- no --- --- no --- --- 
IL-10                 
Zaaqoq; 2014        no  no no no no no --- --- 
IL-16                 
Bank; 2015 --- ---  --- --- ---  --- --- ---  --- ---  --- --- 
IL-17                 
Zaaqoq; 2014        no  no no no no  --- --- 
IL-18                 
Bank; 2015 --- ---  --- --- ---  --- --- ---  --- ---  --- --- 
CXCL-1 (GRO-α)                 
Bank; 2015 --- ---  --- --- ---  --- --- ---  --- ---  --- --- 
Hassanshahi; 
2013 
no --- --- --- --- ---  --- 
--- --- --- --- --- --- no no 
CXCL-9                 
Hassanshahi no --- --- --- --- ---  --- --- --- --- --- --- --- no no 
CXCL-10                 
Hassanshahi; 
2013 
 --- --- --- --- ---  --- 
--- --- --- --- --- --- no no 
CXCL-12                 
Hassanshahi; 
2013 
 --- --- --- --- ---  --- 
--- --- --- --- --- ---  no 
CCL-4 (MIP-1β)                 
Bank; 2015 --- ---  --- --- ---  --- --- --- no --- --- no --- --- 
Zaaqoq; 2014  no no   no no  no no no no   --- --- 
MCP-1                 
Zaaqoq; 2014 no no no no no no no no no no no no no no --- --- 
IP-10                 
Zaaqoq; 2014 no no no no no no no no no no no no no no --- --- 
MIF                 
Bank; 2015 --- ---  --- --- ---  --- --- --- no --- --- no --- --- 
INF-γ                 
Zaaqoq; 2014  no    no no no  no no no no no --- --- 
MMP-2                 
Moghaddam; 
2017 
no no no no no no no no no no no no no no no no 
MMP-8                 
Moghaddam; 
2017 
  no no no no no no no no no no no no no no 
MMP-9                 
Moghaddam; 
2017 
no no no no no no no no no no no no no no  no 
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Ahadi; 2015    --- --- --- --- --- --- --- --- --- --- --- --- --- 
Neurofilament                  
Ahadi; 2015   no --- --- --- --- --- --- --- --- --- --- --- --- --- 
Kuhle; 2014         --- --- --- --- --- --- --- --- 
Ungureanu; 
2014 
   
--- --- --- --- --- --- --- --- --- --- --- --- --- 
NSE                 
Ahadi; 2015   no --- --- --- --- --- --- --- --- --- --- --- --- --- 
Wolf; 2014 no --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
S100-β                 
Wolf; 2014  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
HMGB1                 
Papatheodorou; 
2017 
--- ---  --- --- ---  --- --- --- --- --- --- --- --- --- 
CSF level                 
Neurofilament                  
Ungureanu; 
2014 
   
--- --- --- --- --- --- --- --- --- --- --- --- --- 
NOx                 
Hosaka; 2008 --- --- --- --- no --- --- --- --- --- --- --- --- --- --- --- 
no: No significant difference; : Significantly higher; : Significantly lower. 
CCL: chemokine (C-C motif) ligand; CXCL: Chemokine (C-X-C motif) ligand; GFAP: Glial 
fibrillary acidic protein; HGF: Hepatocyte growth factor; HMGB1: High mobility group box 1 
protein; IL: Interleukin; INF-γ: Interferons-γ; IP-10: Inducible protein-10; MCP: Monocyte 
chemotactic protein; MIF: migration inhibitory factor; MMP: Matrix metalloproteinase; NFH: 
Neurofilament heavy chain; NF-L: Neurofilament light chain; NSE: Neuron specific enolase 
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Table 6: Serum and CSF level of various biomarker in neurologically non-improved spinal cord 
injured patients compered to neurologically improved patients (prognostic value) 
Biomarkers 
  Time after SCI (day) 
0* 1 2 3 4 5 6 7 8 9 10 11 12 13 14 28 56 90 
Serum 
Level 
 
 
                
IL-1                   
Biglari; 
2015 
no no --- no --- --- --- no --- --- --- --- --- --- no no no no 
CCL-2                   
Heller; 2017  no --- no --- --- --- no --- --- --- --- --- --- no no no no 
CCL-3                   
Heller; 2017 no no --- No --- --- --- no --- --- --- --- --- --- no no no no 
CCL-4 (MIP-
1β) 
 
       
          
Heller; 2017  no --- no --- --- --- no --- --- --- --- --- --- no no  no 
CXCL-5                   
Heller; 2017 no no --- no --- --- --- no --- --- --- --- --- --- no no no no 
TNF-α                   
Biglari; 
2015 
 no --- no --- --- no --- --- --- --- --- --- --- no 
no no no 
MMP-2                   
Moghaddam; 
2017 
no no no no no no no no no no no no no no no no no no 
MMP-8                   
Moghaddam; 
2017 
  no no no no no no no no no no no no no no no no 
MMP-9                   
Moghaddam; 
2017 
no no no no no no no no no no no no no no no 
 
no no 
Neurofilament                    
Kuhle; 2014 no        --- --- --- --- --- --- --- --- --- --- 
sCD95L                   
Ferbert; 2017 no no --- no --- --- ---  --- --- --- --- --- --- no no no no 
TGF-β1                   
Ferbert; 
2017 
no no 
--- no --- --- --- no --- --- --- --- --- --- 
no no no no 
IGF-1                   
Ferbert; 2017 no no --- no --- --- --- no --- --- --- --- --- ---  no  no 
Moghaddam; 
2016 
no no 
--- 
no 
--- --- ---  --- --- --- --- --- ---  
no 
 
no 
CSF level                   
IL-6                   
Kwon; 2017 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
IL-8                   
Kwon; 2017 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
MCP-1                   
Kwon; 2017 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Neurofilament                    
Pouw; 2014 --- no --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Ungureanu; 
2014 
 no --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
GFAP                   
Kwon; 2017 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Pouw; 2014 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
NSE                   
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Pouw; 2014 --- no --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
S100-β                   
Kwon; 2017 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Pouw; 2014 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Tau                   
Kwon; 2017 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Pouw; 2014 ---  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
*, time interval between 0 to 12 hours.  
no: No significant difference; : Significantly higher; : Significantly lower. 
CCL: chemokine (C-C motif) ligand; CXCL: Chemokine (C-X-C motif) ligand; GFAP: Glial 
fibrillary acidic protein; IGF-1: Insulin-like growth factor 1; IL: Interleukin; MCP: Monocyte 
chemotactic protein; MMP: Matrix metalloproteinase; NFH: Neurofilament heavy chain; NF-L: 
Neurofilament light chain; NSE: Neuron specific enolase; sCD95L: Serum cluster of differentiation 
95 ligand; TGF- β1: Tumour growth factor β1; TNF-α: Tumour necrosis factor-α 
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